Literature DB >> 11228389

Plant-derived measles virus hemagglutinin protein induces neutralizing antibodies in mice.

Z Huang1, I Dry, D Webster, R Strugnell, S Wesselingh.   

Abstract

Measles remains a significant problem in both the developed and developing world, and new measles vaccination strategies need to be developed. This paper examines the strategy of utilizing transgenic plants expressing a measles antigen for the development of an oral sub-unit measles vaccine. A 1.8 kb fragment encompassing the coding region of the measles virus hemagglutinin (H) protein was cloned into a plant expression cassette. Three different expression constructs were tested: pBinH (H gene alone), pBinH/KDEL (addition of a C-terminal endoplasmic reticulum-retention sequence SEKDEL) and pBinSP/H/KDEL (further addition of an authentic N-terminal plant signal peptide). The highest levels of recombinant H protein production were observed in plants transformed with pBinH/KDEL. Mice inoculated intraperitoneally with transgenic plant derived recombinant H protein produced serum anti-H protein antibodies that neutralized the measles virus (MV) in vitro. Mice gavaged with transgenic tobacco leaf extracts also developed serum H protein-specific antibodies with neutralizing activity against MV in vitro. These results indicate that the plant-derived measles H protein is immunogenic when administered orally and that, with further development, oral vaccination utilizing transgenic plants may become a viable approach to measles vaccine development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11228389     DOI: 10.1016/s0264-410x(00)00390-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Glycosylated F4 (K88) fimbrial adhesin FaeG expressed in barley endosperm induces ETEC-neutralizing antibodies in mice.

Authors:  Jussi J Joensuu; Mirkka Kotiaho; Teemu H Teeri; Leena Valmu; Anna Maria Nuutila; Kirsi-Marja Oksman-Caldentey; Viola Niklander-Teeri
Journal:  Transgenic Res       Date:  2006-06       Impact factor: 2.788

2.  CD46 measles virus receptor polymorphisms influence receptor protein expression and primary measles vaccine responses in naive Australian children.

Authors:  Holly D Clifford; Catherine M Hayden; Siew-Kim Khoo; Guicheng Zhang; Peter N Le Souëf; Peter Richmond
Journal:  Clin Vaccine Immunol       Date:  2012-02-22

Review 3.  Plant-based oral vaccines: results of human trials.

Authors:  C O Tacket
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

4.  Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine.

Authors:  Diane E Webster; Michelle L Cooney; Zhongjun Huang; Damien R Drew; Ian A Ramshaw; Ian B Dry; Richard A Strugnell; Jenny L Martin; Steve L Wesselingh
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

5.  Neutralizing immunogenicity of transgenic carrot (Daucus carota L.)-derived measles virus hemagglutinin.

Authors:  E Marquet-Blouin; F B Bouche; A Steinmetz; C P Muller
Journal:  Plant Mol Biol       Date:  2003-03       Impact factor: 4.076

Review 6.  Farming of Plant-Based Veterinary Vaccines and Their Applications for Disease Prevention in Animals.

Authors:  Pit Sze Liew; Mohd Hair-Bejo
Journal:  Adv Virol       Date:  2015-08-13

Review 7.  Plant-made vaccines for humans and animals.

Authors:  Edward P Rybicki
Journal:  Plant Biotechnol J       Date:  2010-03-11       Impact factor: 9.803

8.  Oral immunization of cattle with hemagglutinin protein of rinderpest virus expressed in transgenic peanut induces specific immune responses.

Authors:  Abha Khandelwal; G Lakshmi Sita; M S Shaila
Journal:  Vaccine       Date:  2003-07-04       Impact factor: 3.641

Review 9.  Plants as bioreactors: Recent developments and emerging opportunities.

Authors:  Arun K Sharma; Manoj K Sharma
Journal:  Biotechnol Adv       Date:  2009-06-30       Impact factor: 14.227

Review 10.  Plant cell factories and mucosal vaccines.

Authors:  Amanda M Walmsley; Charles J Arntzen
Journal:  Curr Opin Biotechnol       Date:  2003-04       Impact factor: 9.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.